Anixa Biosciences Announces Chief Development Officer Dr. Pam Garzone to Speak at the Alliance for Cancer Gene Therapy Summit 2025 on March 19th

Core Viewpoint - Anixa Biosciences, Inc. is actively participating in the Alliance for Cancer Gene Therapy Summit 2025, highlighting its advancements in cancer treatment, particularly in cell and gene therapy for gynecologic and breast cancers [1][2][3] Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a therapeutic portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [5] - The company is also developing vaccines in partnership with Cleveland Clinic to treat and prevent breast and ovarian cancers, as well as other cancer vaccines targeting high incidence malignancies such as lung, colon, and prostate cancers [5] - Anixa employs a unique business model that involves partnering with renowned research institutions throughout all stages of development, allowing for the exploration of emerging technologies in complementary fields [5] Event Participation - Dr. Pam Garzone, Chief Development Officer of Anixa, will be a panelist at the ACGT Summit, discussing advancements in cell and gene therapy, including Anixa's CAR-T therapy for ovarian cancer [2][3] - The panel discussion is scheduled for March 19, 2025, from 11:15 AM to 12:15 PM ET, at the Alexandria Center for Life Science in New York City [1][2]